Through our lung cancer clinical development program, we continue to advance our understanding of the potential of our therapies in earlier lines of therapy – including pre- and post-surgical intervention. A new publication from The Lancet Respiratory Medicine (a journal from The Lancet) shared new interim analysis data of perioperative treatment with our PD-1 inhibitor plus neoadjuvant chemotherapy in patients with resectable #NSCLC. Check out the study here: https://bit.ly/4fCbnsp. #LungCancer
关于我们
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook.
- 网站
-
https://www.beigene.com
BeiGene的外部链接
- 所属行业
- 生物技术研究
- 规模
- 超过 10,001 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
- 创立
- 2010
- 领域
- targeted therapy、immuno-oncology、hematology、oncology和cancer
地点
BeiGene员工
-
Andrew Harmon
Clinical recruiter at BeiGene
-
Roger Ralph TSCHOPP M.D., M.Sc.
Senior Medical Director, Global Medical Affairs at BeiGene
-
Scott Carter
VP, Associate General Counsel, Business Development at BeiGene
-
Alex Emanuel
Healthcare marketer, commercial operations and analytics professional
动态
-
Thanks to Jefferies and London for hosting John V. Oyler, Aaron Rosenberg, CFA, and Mark Lanasa. We enjoyed the fireside chat led by Kelly Shi, providing updates on our CLL franchise, the breadth of our solid tumor pipeline and our global progress. https://bit.ly/3B0RtZ5
-
-
Meet Raheem Slaughter, one of our dedicated colleagues, as he gives us an inside look at BeiGene's manufacturing process at our new facility in Hopewell, N.J. For Raheem, this work is more than just a job—it’s a personal mission, as his own family has been affected by the disease we’re working to treat. ? Watch the video to hear Raheem’s story and see how passion drives progress.
-
Our colleagues in Australia recently volunteered at the Brisbane Ekka, serving ice cream sundaes to help raise support for The Common Good, an initiative of The Prince Charles Hospital Research Foundation. The Foundation plays a critical role in funding medical research and advancing patient care across Australia. We’re proud to be part of such an impactful cause and grateful for the opportunity to make a difference. #PatientsFirst #GivingBack #TheCommonGood
-
-
At BeiGene, we're committed to leading with science to transform cancer care. This includes innovating across therapeutic technologies, and we are unveiling some of our advances in cell therapy at #ASH2024. #CellTherapy #iPSC?
I am excited to share the first public reveal of BeiGene’s tremendous progress made on iPSC-derived γδ T cells at ASH 2024. Though our very first experiment was initiated only 2.5 years ago amidst ongoing laboratory construction and pandemic, fast forward to this day, we have already 1) generated a proprietary, well-characterized GMP grade iPSC clone collection designated for our future γδ T and αβ T cellular products, 2) established our unique efficient, enrichment-free, feeder-free methodologies that deliver impressively high purity and high expansion fold for our iPSC derived γδ T and iPSC derived CD8 αβ T platforms, and 3) engineered proprietary genetic elements that further enhance the longevity and potential efficacy of our effector cell populations. Our platforms are designed to allow plug-and-play for a variety of CAR-T and TCR-T cell therapies with potential to address unmet needs in diverse indications. The ongoing efforts of a talented and committed cell therapy research team, along with incredible empowerment and support from the BeiGene’s executive team, have enabled these exciting technology achievements within a short period of time. I truly believe that the success of #iPSC-derived cell therapies will not only dramatically reduce the cost-of-goods but also enhance the accessibility of cell therapies, hence democratizing the application of these transformative medicines globally. The team and I are looking forward to sharing more at ASH and contributing to advancing research in this important field through conversations with experts, industry peers, and future partners. Please feel free to reach out to me on LinkedIn to learn more. Onward and upward! See our ASH abstract here: https://bit.ly/3UDBK97 #ASH2024 #CellTherapy #iPSC-Derived
-
Cancer touches not just the individual but the entire family. This National Family Caregivers Month, we celebrate the selfless individuals who provide critical support to those affected by cancer. Caregivers—whether spouses, children, friends or neighbors—are essential to the emotional and physical well-being of patients. Let’s come together to express our gratitude for these unsung heroes. Discover more at https://bit.ly/3YRJ4Pz. #NationalFamilyCaregiversMonth #NFCMonth
-
As we celebrate the 5th anniversary of our BTK inhibitor’s approval, we’re proud to share that over 140,000 patients worldwide have been treated with this medicine across five different indications. Our commitment to expanding access and advancing cancer care remains at the heart of our mission. Today, our BTK inhibitor stands as the cornerstone of our hematology leadership, improving outcomes for patients with certain blood cancers in over 70 markets. Watch the video to learn more. #BloodCancer #BTKi #PatientsFirst????
-
BeiGene转发了
Today BeiGene unveiled our proposed company name change to BeOne Medicines Ltd., reaffirming our mission to unite the global community against cancer.?The new name is part of a broader strategic growth plan that has enabled the Company’s fast rise to global leadership since its inception in 2010. Read my latest LinkedIn article for more background.?
BeiGene Unveils Proposed Name Change to BeOne Medicines
John V. Oyler，发布于领英
-
Today we unveiled our proposed name change to BeOne Medicines Ltd.?Reaffirming our mission to unite the global community against cancer. Read the press release for full details:?https://bit.ly/48Oxfyg
-
'I'm extremely proud to be part of this company because I know what we are doing is having a huge impact worldwide.' Our colleague, Gabrielle McEntee, shares her inspiration and motivation for working at BeiGene. Watch the video to discover more.